PRFX PRF Technologies Ltd. Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1801834 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY65.6%
TTM EPS YoY92.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-311.8%
Operating margin-30,129.4%
Net margin-29,541.2%
FCF margin-23,276.5%
EBITDA margin-30,041.2%
Returns
ROE-96.9%
ROA-60.8%
ROIC (approx.)-271.5%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets22.6%
Debt / equity0.00x
Current ratio1.78x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-12.9%
Payout ratio—
Capex / revenue11.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $17,000 | $0 | $0 | — | — |
| Cost of revenue | $70,000 | $0 | $0 | — | — |
| Gross profit | -$53,000 | $0 | $0 | — | — |
| R&D expense | $1.14M | $11.71M | $6.04M | $4.42M | $2.86M |
| SG&A expense | $1.40M | $1.32M | $1.68M | $2.09M | $2.15M |
| Operating income | -$5.12M | -$14.67M | -$9.58M | -$8.87M | -$7.21M |
| Pretax income | -$5.01M | -$14.58M | -$9.34M | -$8.78M | -$7.24M |
| Income tax | $8,000 | $8,000 | $8,000 | $9,000 | $6,000 |
| Net income | -$5.02M | -$14.59M | -$9.34M | -$8.79M | -$7.25M |
| EBITDA | -$5.11M | -$14.66M | -$9.57M | -$8.85M | -$7.20M |
| EPS (basic) | -7.47 | -105.52 | -122.94 | -63.46 | -7.25 |
| EPS (diluted) | -7.47 | -105.52 | -122.94 | -63.46 | -7.25 |
| Weighted avg. shares (diluted) | 647,973 | 138,254 | 76,005 | 138,548 | 999,562 |
| Banking | |||||
| Net interest income | — | — | — | $0 | $0 |
| Balance sheet | |||||
| Cash & equivalents | $3.12M | $4.26M | $8.03M | $4.11M | $16.57M |
| Short-term investments | — | — | $0 | $6.08M | $0 |
| Current assets | $4.35M | $4.43M | $9.80M | $12.28M | $19.02M |
| PP&E, net | $30,000 | $35,000 | $38,000 | $44,000 | $53,000 |
| Goodwill | $186,000 | $0 | — | — | — |
| Intangibles | $7.41M | $0 | — | — | — |
| Total assets | $12.00M | $4.53M | $9.93M | $12.33M | $19.07M |
| Current liabilities | $2.44M | $2.44M | $2.41M | $1.06M | $757,000 |
| Total liabilities | $2.71M | $2.70M | $2.69M | $1.31M | $991,000 |
| Shareholders' equity | $8.54M | $1.82M | $7.24M | $11.02M | $18.08M |
| Shares outstanding | 830,613 | 341,827 | 165,489 | 1.08M | 10.48M |
| Cash flow statement | |||||
| Operating cash flow | -$3.96M | -$12.62M | -$6.68M | -$6.46M | -$6.55M |
| Capital expenditure | $2,000 | $13,000 | $9,000 | $6,000 | $50,000 |
| Free cash flow | -$3.96M | -$12.63M | -$6.69M | -$6.46M | -$6.60M |
| Investing cash flow | -$982,000 | -$13,000 | $5.99M | -$6.01M | -$50,000 |
| Financing cash flow | $3.82M | $8.86M | $4.62M | $0 | $7.48M |
| Depreciation & amortization | $15,000 | $16,000 | $15,000 | $15,000 | $7,000 |
| Stock-based compensation | $447,000 | $310,000 | $804,000 | $1.39M | $812,000 |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.